Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The product supplies functional factor VIII, which participates in the intrinsic coagulation pathway, and von Willebrand factor, which promotes platelet adhesion and stabilizes factor VIII. Together they restore the normal clotting cascade, allowing effective formation of a fibrin clot and reducing bleeding.

Dosing of Immunate is individualized and determined by the prescribing clinician based on the patient’s weight, severity of deficiency, type of procedure, and laboratory monitoring. The prescriber calculates the required units to achieve target factor levels and adjusts subsequent doses as needed.

Limited clinical data are available for use of factor VIII/VWF concentrates in pregnancy and lactation. The potential benefits should be weighed against any unknown risks, and treatment decisions should be made by a specialist in consultation with the obstetric team.

To order Immunate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Immunate is a plasma‑derived concentrate containing both factor VIII and von Willebrand factor, whereas many alternatives are recombinant single‑component products (e.g., recombinant factor VIII). The combined formulation can simplify dosing for patients who need both activities, but recombinant products may have a lower risk of pathogen transmission.

Immunate must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the product. Do not use if the solution appears discolored or contains particles.

Immunate is given by intravenous infusion. The recommended infusion rate and total dose are set by the treating physician and are based on the patient’s clinical condition and laboratory results. Infusion should be performed under medical supervision with appropriate monitoring for reactions.

The most serious risks include the development of neutralizing antibodies (inhibitors) against factor VIII or VWF, severe allergic or anaphylactic reactions, and thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Immediate medical attention is required if any of these occur.

Immunate is contraindicated in individuals with a known hypersensitivity to any of its components, including human plasma proteins. Patients with a history of severe allergic reactions to factor concentrates should avoid its use until evaluated by a specialist.